Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism

Gemcitabine (GEM, 2′,2′-difluorodeoxycytidine) is currently used in advanced pancreatic adenocarcinoma, with a response rate of < 20%. The purpose of our work was to improve GEM activity by addition of cannabinoids. Here, we show that GEM induces both cannabinoid receptor-1 (CB1) and cannabinoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Donadelli, M, Dando, I, Zaniboni, T, Costanzo, C, Dalla Pozza, E, Scupoli, M T, Scarpa, A, Zappavigna, S, Marra, M, Abbruzzese, A, Bifulco, M, Caraglia, M, Palmieri, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122066/
https://www.ncbi.nlm.nih.gov/pubmed/21525939
http://dx.doi.org/10.1038/cddis.2011.36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122066/
https://www.ncbi.nlm.nih.gov/pubmed/21525939
http://dx.doi.org/10.1038/cddis.2011.36

Ejemplares similares